Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsWalter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.
Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.
FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma
Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma
IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation
Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis
GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM
1.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
2.
For incarcerated people, study shows gaps exist in quality of cancer care
3.
Updates from the 2022 WHO classification of kidney epithelial tumors
4.
New research uncovers link between cancer pathway and blood-retina barrier function
5.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
1.
The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer
2.
Unveiling the Mystery of Castleman's Disease: A Journey to Better Health
3.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
4.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
5.
Unlocking the Secrets of Blood Production: The Journey and Regulation of Hematopoietic Stem Cells
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge